Spectral Molecular Imaging, a wholly-owned subsidiary of Cascade Technologies, has completed the development of its initial product SkinSpect, aimed at early detection of melanoma.

SkinSpect incorporates hyperspectral imaging, autofluorescence measurement and polarization-gated detection, according to Erik H. Lindsley, PhD, president of Beverly Hills, Calif.-based Spectral.

Lindsley added that the software controlling image acquisition and handling is driven by an interface allowing data and patient monitoring, image archiving and analysis, and internet-based data transfer and tele-consultations. Its design is compliant with and conducive to EMR generation and tracking.